66. IgA nephropathy Clinical trials / Disease details
Clinical trials : 275 / Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-005609-28-ES (EUCTR) | 18/03/2022 | 03/01/2022 | Study to assess whether the drug Ravulizumab works in patients with kidney problems due to IgA immunoglobulin and who do not respond to corticosteroids | A PILOT PROOF-OF–CONCEPT STUDY TO ASSESS THE EFFICACY AND SAFETY OF A 6 MONTHS RAVULIZUMAB TREATMENT IN PATIENTS WITH FLARES OF CORTICOSTEROID-RESISTANT IDIOPATHIC IgA NEPHROPATHY | Treatment for IgA nephropathy flares;Therapeutic area: Body processes [G] - Immune system processes [G12] | Trade Name: Ultomiris 300 mg/30 ml INN or Proposed INN: Ravulizumab Other descriptive name: ALXN1210 | Dr. Alfons Segarra Medrano | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 1 | Phase 4 | Spain |